Full-Time
Develops, produces, and markets diagnostic tests
$77k - $100k/yr
Bridgewater Township, NJ, USA + 1 more
More locations: Rochester, NY, USA
In Person
Onsite role; requires in-person presence in Rochester, NY or Raritan, NJ.
Bachelor's
See people who can refer or advise you
QuidelOrtho provides in vitro diagnostics (IVD) products, including diagnostic tests and equipment that use immunoassay and molecular testing to detect medical conditions. Its products are used in point-of-care settings, clinical laboratories, and transfusion medicine, serving individual healthcare providers to large institutions. The company develops and manufactures these tests and devices, which run on specialized platforms or point-of-care instruments to analyze patient samples and deliver quick, accurate results. What sets QuidelOrtho apart is its long history and the combination of Quidel’s and Ortho’s expertise into a broad portfolio, with a global reach and long-term contracts with healthcare providers. The company’s goal is to improve diagnostic accuracy and efficiency to support better patient outcomes and broad access to essential diagnostic solutions.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
San Diego, California
Founded
1937
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Paid Vacation
Paid Sick Leave
Paid Holidays
Employee Assistance Program
Wellness Program
QuidelOrtho Corporation has risen 31.7% over three months, but faces headwinds that may limit further gains. The diagnostics company reported second-quarter revenues of $630.9 million, up 2.8% year over year, with Labs, Immunohematology and Point of Care segments all posting growth. Excluding China, revenues grew 6% at constant currency. Adjusted EBITDA increased 21% to $129 million, reaching a 20.5% margin, supported by ongoing cost optimisation efforts targeting $50 million in net savings through 2027. However, China revenues fell 23.3% at constant currency due to distributor inventory reductions ahead of pricing changes. Management expects these challenges to persist through 2026. QuidelOrtho lowered its full-year revenue guidance to $2.52-$2.60 billion from $2.70-$2.75 billion, and cut adjusted earnings guidance to 65-90 cents per share from $1.80-$2.00, citing China weakness and conservative respiratory season assumptions.
QuidelOrtho reported second-quarter revenues of $630.9 million, up 2.8% year-over-year and exceeding analyst expectations by 2.1%. The company, formed from the 2022 merger of Quidel and Ortho Clinical Diagnostics, develops diagnostic testing solutions for healthcare providers. Chief executive Brian Blaser noted strong performance across core franchises and regions, except China, where proposed IVD pricing guidelines and softer respiratory demand created headwinds. The broader healthcare equipment and supplies sector showed strength in Q2, with 36 tracked stocks beating revenue estimates by 2% on average. However, next quarter's guidance came in 1.7% below consensus. QuidelOrtho's shares fell 12.3% following its earnings announcement, which included weaker full-year guidance than peers. The stock currently trades at $14.31.
QuidelOrtho's second-quarter results prompted investor concern despite beating revenue and earnings estimates. CEO Brian Blaser cited a "softer respiratory environment" and pronounced weakness in China as primary challenges impacting performance. Revenue reached $630.9 million, beating analyst estimates of $618.1 million. Adjusted earnings per share came in at $0.13, significantly above the expected -$0.05. However, the company lowered its full-year revenue guidance to $2.56 billion from $2.73 billion, a 6.1% decrease. Management also reduced full-year adjusted EPS guidance to $0.78, down 59.2%. China revenue fell sharply due to uncertainty around new in-vitro diagnostics pricing guidelines. CFO Micah Young outlined plans to improve working capital and reduce inventory to support deleveraging. The CEO declined to comment on media speculation regarding a potential point-of-care business sale.
QuidelOrtho reported second quarter 2026 revenue of $631 million, up 3% year-over-year. Excluding China, total revenue grew 6%. The diagnostics solutions provider saw Labs revenue reach $383 million and Point of Care revenue hit $108 million, growing 16%. The company reported a GAAP net loss of $93 million and adjusted EBITDA of $129 million. However, challenges in China related to proposed in vitro diagnostics pricing guidelines impacted performance. QuidelOrtho reduced its full-year 2026 revenue guidance to $2.52-$2.60 billion from $2.70-$2.75 billion previously. Adjusted EBITDA guidance was lowered to $540-$560 million from $615-$630 million. The company withdrew its free cash flow guidance as it works through working capital impacts. Chief executive Brian Blaser cited demand headwinds in China and a softer global respiratory environment as reasons for the revision.
QuidelOrtho Corporation (NASDAQ:QDEL) receives consensus rating of "Reduce" from analysts. July 29, 2026 Key points. * Analysts maintain a cautious view of QuidelOrtho: six firms assign the stock a consensus "Reduce" rating, including two sells and four holds. The average 12-month price target is $13.63, below the reported opening price of $16.67. * QuidelOrtho's latest quarterly results missed expectations, with a $0.04 loss per share versus the anticipated $0.37 profit and revenue of $619.8 million versus $665.2 million expected. Revenue declined 10.5% year over year, while the company reported a negative 45.57% net margin. * Institutional ownership remains high at 99%: several hedge funds increased their positions, including Segall Bryant & Hamill, which added 29.2% to its holdings, and GAMMA Investing, which raised its stake by 67.7%. * MarketBeat previews top five stocks to own in August. Shares of QuidelOrtho Corporation (NASDAQ:QDEL - Get Free Report) have been given an average rating of "Reduce" by the six ratings firms that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $13.6250. QDEL has been the topic of several research analyst reports. Zacks Research upgraded shares of QuidelOrtho from a "strong sell" rating to a "hold" rating in a research report on Monday, June 15th. UBS Group reiterated a "neutral" rating and issued a $12.00 price target on shares of QuidelOrtho in a report on Thursday, May 7th. Weiss Ratings reissued a "sell (e+)" rating on shares of QuidelOrtho in a report on Friday, July 17th. Jefferies Financial Group restated a "hold" rating on shares of QuidelOrtho in a research report on Monday, June 29th. Finally, Citigroup increased their target price on shares of QuidelOrtho from $13.00 to $18.00 and gave the company a "neutral" rating in a report on Wednesday, July 8th. QuidelOrtho stock down 1.0%. QDEL opened at $16.67 on Wednesday. The company has a debt-to-equity ratio of 1.33, a current ratio of 1.43 and a quick ratio of 0.80. The business has a 50 day simple moving average of $15.10 and a 200-day simple moving average of $18.41. The stock has a market capitalization of $1.14 billion, a P/E ratio of -0.94 and a beta of 0.69. QuidelOrtho has a 12 month low of $9.92 and a 12 month high of $35.58. QuidelOrtho (NASDAQ:QDEL - Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.04) earnings per share for the quarter, missing analysts' consensus estimates of $0.37 by ($0.41). The business had revenue of $619.80 million during the quarter, compared to analysts' expectations of $665.23 million. QuidelOrtho had a negative net margin of 45.57% and a positive return on equity of 4.25%. The firm's quarterly revenue was down 10.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.74 earnings per share. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. On average, equities analysts anticipate that QuidelOrtho will post 1.87 earnings per share for the current fiscal year. Hedge funds weigh in on QuidelOrtho. Several hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC raised its holdings in QuidelOrtho by 67.7% during the second quarter. GAMMA Investing LLC now owns 2,185 shares of the company's stock worth $38,000 after purchasing an additional 882 shares during the last quarter. Moody National Bank Trust Division boosted its position in QuidelOrtho by 1.1% during the second quarter. Moody National Bank Trust Division now owns 70,748 shares of the company's stock worth $1,239,000 after purchasing an additional 789 shares in the last quarter. Segall Bryant & Hamill LLC grew its holdings in QuidelOrtho by 29.2% in the first quarter. Segall Bryant & Hamill LLC now owns 1,543,410 shares of the company's stock valued at $25,358,000 after purchasing an additional 348,549 shares during the last quarter. Edgestream Partners L.P. acquired a new stake in QuidelOrtho in the first quarter valued at $1,937,000. Finally, Amundi increased its position in shares of QuidelOrtho by 50.0% in the first quarter. Amundi now owns 20,989 shares of the company's stock valued at $345,000 after buying an additional 6,996 shares in the last quarter. 99.00% of the stock is owned by hedge funds and other institutional investors. About QuidelOrtho. QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks. Discover more AI Infrastructure Stocks The company's product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider QuidelOrtho, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and QuidelOrtho wasn't on the list. While QuidelOrtho currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys. Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.